Drug Trial Radar · NCT07705568
An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- EyevensysIndustry
- Sponsor type
- Industry
- First posted
- Jul 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goals of this interventional study are (1) to evaluate the safety and tolerability of multiple doses of PST-611 in men and women over the age of 65 with geographic atrophy secondary to age-related macular degeneration and (2) to assess efficacy of multiple doses of PST-611 by assessing retinal morphology and visual function changes over time. Participants will: * receive one dose every 20 weeks, for a total of 3 doses. * will be followed up for a total of 52 weeks following the first PST-611 dose.
Conditions
- Geographic Atrophy
- Age - Related Macular Degeneration (AMD)
Interventions
PST-611Biological
PST-611 is a naked plasmid DNA encoding human transferrin administered into the ciliary muscle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of ocular and non-ocular adverse events (Safety and Tolerability)Time frame: Screening to week 52
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
CHU de Grenoble-Hôpital Michallon
Grenoble, France, France
Hôpital Lariboisière
Paris, France, France
Hôpital Cochin
Paris, France, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.